Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.59 |
| ▸ | SELP | P16109 | 8/20 | 0.54 |
| ▸ | MAG | P20916 | 5/20 | 0.52 |
| ▸ | SELL | P14151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361662 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30739464 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30173253 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL29600828 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL16449748 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30651675 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30712647 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30913852 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30650429 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30739475 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113474451-B | Dorsal oligodendrocyte progenitor cells from human pluripotent stem cells | 阿斯特里亚斯生物疗法股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-120060141-A | Dorsal oligodendrocyte progenitor cells from human pluripotent stem cells | 阿斯特里亚斯生物疗法股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120060140-A | Method for differentiating pluripotent stem cells in dynamic suspension culture | 谱系细胞疗法股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-20220152167-A1 | IMMUNOGENIC FORMULATIONS FOR TREATING CANCER | UNIVERSIDAD DE CHILE (CL) | 2022-05-19 | — | — | US | claimed |
| US-20250208046-A1 | METHOD FOR PREDICTING GENE TRANSFER RATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| CN-113474451-B | Dorsal oligodendrocyte progenitor cells from human pluripotent stem cells | 阿斯特里亚斯生物疗法股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-120060141-A | Dorsal oligodendrocyte progenitor cells from human pluripotent stem cells | 阿斯特里亚斯生物疗法股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120060140-A | Method for differentiating pluripotent stem cells in dynamic suspension culture | 谱系细胞疗法股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-113646422-B | Method for differentiating pluripotent stem cells in dynamic suspension culture | 谱系细胞疗法股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119563110-A | Diagnostic markers | 巴凯乐诊断有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4502172-A1 | METHOD FOR PREDICTING GENE TRANSFER RATE | Takeda Pharmaceutical Company Limited (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-119301267-A | Method for predicting gene transfer rate | 武田药品工业株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-113905607-B | Heterocyclic compound and harmful arthropod control composition containing same | 住友化学株式会社 | 2022-12-27 | — | — | CN | disclosed |
| CN-115504924-A | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-111712497-B | Heterocyclic compound and noxious arthropod control agent containing same | 住友化学株式会社 | 2022-10-18 | — | — | CN | disclosed |
| CN-110831629-B | Combinations comprising ABX196 for the treatment of cancer | ABIVAX公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-114867491-A | Recombinant MVA viruses for intratumoral and/or intravenous administration for the treatment of cancer | 巴法里安诺迪克有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20220152167-A1 | IMMUNOGENIC FORMULATIONS FOR TREATING CANCER | UNIVERSIDAD DE CHILE (CL) | 2022-05-19 | — | — | US | disclosed |
| CN-105535938-B | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels | 阿塞勒隆制药公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-111298241-B | Improved automatic injector | 安进公司 | 2022-04-05 | — | — | CN | disclosed |